Report Highlights

U.S. LDL Testing: Market Overview

The U.S. LDL cholesterol testing market is valued at USD 2.85 billion in 2024 and is forecast to reach USD 4.25 billion by 2032. Demand is anchored by standard lipid panels and direct LDL assays performed across hospital laboratories, independent reference laboratories, and physician office settings. Private clinical laboratories have led commercial growth, with Quest Diagnostics and Labcorp processing the bulk of outpatient volume. Repeat testing after statin initiation accounts for a rising share of that volume.

Government has shaped the market's structure mainly through payment rules rather than direct procurement. CMS administers the Medicare Clinical Laboratory Fee Schedule, which sets reimbursement for CPT 83721 direct LDL and CPT 80061 lipid panels, while the Department of Veterans Affairs is the principal public purchaser through national laboratory contracts. Assay manufacturing remains entirely private, led by Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, and Beckman Coulter. The private sector therefore sets assay performance, while federal rules set price and access.

Policy-Driven Growth in U.S. LDL Testing

The Affordable Care Act's Section 2713 requires private health plans to cover USPSTF A and B recommended preventive services without cost sharing, which covers lipid screening for eligible adults. Section 4104 of the same Act created the Medicare cardiovascular screening blood tests benefit, covering LDL-inclusive lipid panels once every five years at no beneficiary cost. This converts a discretionary test into a guaranteed reimbursed encounter, lifting volume among roughly 68 million Medicare beneficiaries.

The 2018 AHA/ACC Guideline on the Management of Blood Cholesterol converted LDL-C into the primary treatment target, pushing clinicians toward serial measurement after statin initiation. The Supreme Court's June 2025 decision in Kennedy v. Braidwood Management upheld the USPSTF appointment structure, preserving the no-cost preventive mandate that funds this screening. Together these mechanisms turn guideline-driven monitoring into predictable repeat-testing volume for laboratories. Commercial payers mirror these rules in plan design, extending the mandate beyond Medicare.

Regulatory Barriers and Compliance Costs in U.S. LDL Testing

Every U.S. laboratory performing LDL testing must hold a CLIA certificate issued by CMS under the Clinical Laboratory Improvement Amendments of 1988, with certificate fees scaled to annual test volume and biennial proficiency testing for regulated analytes. Laboratories in New York must also obtain approval through the New York State Department of Health Clinical Laboratory Evaluation Program, which adds several months to market entry. Non-compliant sites face civil money penalties administered by CMS under 42 CFR Part 493.

Assay manufacturers face FDA premarket review under the Federal Food, Drug, and Cosmetic Act, with most direct LDL reagents cleared through 510(k) submissions against a 90-day review goal. The FDA's May 2024 Laboratory Developed Tests final rule was vacated by the Eastern District of Texas in March 2025, leaving in-house assays under CLIA alone. Direct-to-consumer kits also fall under the FTC Health Breach Notification Rule, amended in 2024, which requires breach notification for health data held by testing platforms.

Policy-Created Opportunities in the United States

The PAMA-driven reset of Medicare Clinical Laboratory Fee Schedule rates creates an opening for point-of-care LDL analyzers in pharmacies and community clinics. Abbott's Cholestech LDX platform holds CLIA waiver status, allowing retail pharmacy chains and federally qualified health centers to deliver same-visit lipid results. Operators in these settings can bill standardized CPT codes under a Certificate of Waiver rather than full CLIA certification.

Medicaid expansion in 40 states and the District of Columbia, combined with HRSA's Health Center Program, which receives more than USD 5 billion in annual appropriations, funds federally qualified health centers that screen uninsured adults. These sites represent a procurement channel for bulk direct LDL assay reagents from Siemens Healthineers and Beckman Coulter, whose high-volume chemistry analyzers suit health-center throughput. Health center screening programs also create demand for standardized reporting aligned with the 2018 AHA/ACC targets.

Market at a Glance

Leading Market Participants

• Quest Diagnostics
• Labcorp
• Roche Diagnostics
• Abbott Laboratories
• Siemens Healthineers
• Beckman Coulter
• Bio-Rad Laboratories
• Sonic Healthcare USA
• Everlywell
• LetsGetChecked

Regulatory and Policy Environment

The primary legislation is the Clinical Laboratory Improvement Amendments of 1988, codified at 42 U.S.C. 263a and administered by CMS, with FDA responsible for device review under the Federal Food, Drug, and Cosmetic Act. Compliance requires CLIA certification, biennial proficiency testing for regulated analytes, personnel qualification standards, and HIPAA-compliant handling of patient results. The most consequential upcoming change is the PAMA rate reset, which uses private payer data to recalibrate Medicare Clinical Laboratory Fee Schedule rates for codes including 83721 and 80061.

Compared with regional peers, the U.S. framework is fragmented. Canada relies on provincial laboratory licensing and Health Canada medical device licensing, delivering uniform single-payer access, while the EU In Vitro Diagnostic Regulation (EU) 2017/746 sets CE-marking transition deadlines of December 2027 for Class D devices and December 2028 for Class C. Following the March 2025 vacatur, the U.S. imposes no premarket review on in-house LDTs, making it the most permissive major market for laboratory-developed LDL assays.

Long-Term Policy Outlook for U.S. LDL Testing

By 2032, the PAMA fee reset will shift Medicare reimbursement toward high-throughput reference laboratories and compress independent hospital laboratory margins. The Medicare Clinical Laboratory Fee Schedule will remain the pricing benchmark for commercial payers, which reference CMS rates in contract negotiations. Expect further consolidation as Quest Diagnostics and Labcorp absorb outreach testing volume previously held by community hospitals. Pricing pressure will also favor assays with automated direct LDL workflows over calculated methods.

Policy will also expand testing into home and pharmacy settings. The FTC Health Breach Notification Rule will drive consent and data-security investment at direct-to-consumer providers such as Everlywell and LetsGetChecked, raising compliance costs for smaller entrants. Growing use of lipoprotein(a) measurement under cardiovascular guidance will expand the test menu alongside direct LDL, increasing reimbursed encounters through 2032. Providers that build HIPAA and FTC compliance into their platforms before 2028 will capture this volume.